MetaCap

Pharming Group N.V. ADS (PHAR)

NASDAQ: PHARHealth CareBiotechnology: Pharmaceutical PreparationsUSD

11.54-0.62 (-5.10%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PHAR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$816.78M
52-week range
9.11 – 21.34
Day range
11.30 – 11.97
Volume / Avg
10.51K / 21.33K
Beta
—

52-week range

$9.11$21.34

PHAR stock today

Shares of Pharming Group N.V. (PHAR) finished lower on Nov 20 at $11.54, a drop of 5.10% or $0.62 per share, versus the S&P 500's 3.70% decline. Trading was light, with 10.51K shares changing hands, about 49% of the average daily volume. Shares are 45.9% below their 52-week high of $21.34, set on Jan 27, 2026 and 26.7% above the 52-week low of $9.11, near the bottom of the past year's range.

PHAR is down 34.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 29.0%. Pharming Group N.V. trades at 36.1x its trailing twelve-month earnings per share of $0.32. Its forward P/E of 64.1x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Pharming Group N.V.

Company profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Kenneth Lynard EMBA, M.Sc.
Headquarters
Leiden
Employees
407

Financial highlights

Full financials

In fiscal 2025, Pharming Group N.V. generated $376.1 million in revenue, up 26.6% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $2.9 million, for a net margin of 0.8% versus a median of 6.7% in the prior 5 years. Gross margin was 87.9% (down from 88.1%) and operating margin 6.9%.

Pharming Group N.V. annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$376.13M$297.20M$245.32M$205.62M$198.87M
Growth+26.56%+21.15%+19.30%+3.39%-6.27%
Net income$2.85M$-11.84M$-10.55M$13.67M$16.00M
EPS (diluted)$0.004$-0.018$-0.016$0.019$0.023

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$35.70+209.36%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $25.80High $41.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 27, 2026
EPS actual vs est.
$0.10 vs $0.33
Surprise
-69.70%

PHAR news

All PHAR news

Pharming Group N.V. peers

Health Care sector
PHAR peer companies
CompanyPrice% ChgMarket capCompare
CRVSCorvus Pharmaceuticals Inc.9.67-3.40%$815.69Mvs PHAR
VSTMVerastem Inc.6.33-7.73%$797.67Mvs PHAR
SNDXSyndax Pharmaceuticals Inc.8.72-4.49%$785.05Mvs PHAR
IRWDIronwood Pharmaceuticals Inc. Class A4.70-0.21%$778.09Mvs PHAR
MTRIMentari Therapeutics Inc.14.70-3.57%$856.94Mvs PHAR
LTGOLatigo Biotherapeutics Inc.13.00-1.81%$861.89Mvs PHAR
COLLCollegium Pharmaceutical Inc.24.72-1.94%$768.18Mvs PHAR
ORICOric Pharmaceuticals Inc.7.36-4.42%$764.94Mvs PHAR

Indexes, lists and sector

Pharming Group N.V. stock FAQ

What is Pharming Group N.V.'s stock price today?

PHAR last traded at $11.54 as of Nov 20, 4:00 PM EST, down 5.10% on the day. Prices are delayed at least 15 minutes.

What is PHAR's P/E ratio?

PHAR trades at a trailing P/E ratio of 36.06 and a forward P/E of 64.11.

Who is Pharming Group N.V.'s CEO?

Mr. Kenneth Lynard EMBA, M.Sc. is the chief executive officer of Pharming Group N.V. ADS, which has about 407 employees.

What is the PHAR 52-week high?

The 52-week high for PHAR is $21.34 and the 52-week low is $9.11. The stock is currently 45.9% below its high.

Compare PHAR